Reports
Sale
Liver Disease Treatment Market Size, Share, Trends, Report: By Treatment Type: Antiviral Drugs, Immunosuppressants, Vaccines, Corticosteroids, Immunoglobins, Targeted Therapy, Chemotherapy, Others; By Disease Type: Hepatitis, Autoimmune Diseases, Others; By End User; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Liver Disease Treatment Market Size
The liver disease treatment market was valued at USD 20.14 billion in 2023, driven by the increasing prevalence of liver disease across the 8 major markets. The market is expected to grow at a CAGR of 10.4% during the forecast period of 2024-2032, with the values likely to reach USD 48.88 billion by 2032.
Liver Disease Treatment Market Outlook
- Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. This rising burden of liver disease is a major growth driver for effective treatments.
- The surge in the approval of innovative drugs for the treatment of liver disease by the regulatory bodies is a significant market trend.
- The market value is impacted by the rising preference for combination therapies and the advancements in diagnostic technologies.
Liver Disease Treatment Market Overview
A liver disease directly affects the liver and progresses slowly unlike acute liver failure. Untreated liver disease can result in liver cancer or liver failure. Treatments for liver disease can include antiviral drugs to treat hepatitis, steroids for managing liver inflammation, and others. The increasing cases of liver disease due to factors such as obesity, viral infections, and alcohol consumption is a major growth driver of the market. Further, the rising development of novel therapeutics such as immune modulators and gene therapies that offer better clinical benefits are expected to augment the market demand. Moreover, improvements in diagnostic tools including imaging techniques and biomarker tests for diagnosing and monitoring liver diseases is also contributing to the market growth.
Liver Disease Treatment Market Growth Drivers
Rising Prevalence of Liver Diseases to Drive Market Growth
Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. It is reported that 4.5 million adults have been diagnosed with liver disease. However, around 80 to 100 million U.S. adults are estimated to have undiagnosed fatty liver disease in varying stages. The increasing prevalence of liver diseases is expected to drive the demand for effective treatment. Additionally, the growing geriatric population, which is more prone to liver diseases, is poised to contribute to the market demand.
Liver Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Increased Public Health Initiatives to Impact the Market Landscape
The market is witnessing increased awareness campaigns and screening programs by global health organizations and governments in order to promote early diagnosis and treatment of liver disease. Such public health initiatives, especially for diseases like hepatitis B and C, are encouraging more people to seek treatment. These factors are likely to influence the market landscape signficantly.
Surge in FDA Approval to Meet Rising Liver Disease Treatment Market Demand
In March 2024 , Rezdiffra™ developed by biopharma company Madrigal Pharmaceuticals, Inc. became the first and only FDA-approved treatment for noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Moreover, in February 2024 , GSK plc's investigational candidate bepirovirsen received Fast Track designation for the treatment of chronic hepatitis B (CHB) by the FDA. The surge in the approval of innovative drugs for the treatment of liver disease, supported by the presence of a favorable regulatory environment is a major trend, poised to amplify the market demand in coming years.
Advancements in Diagnostic Technologies Likely to Boost Liver Disease Treatment Market Size
The rising advancements in imaging technologies, such as transient elastography (FibroScan), magnetic resonance elastography (MRE), and multiparametric MRI are experiencing popularity among patients due to their non-invasive assessment of liver fibrosis and steatosis. The increasing availability of non-invasive diagnostic tools is anticipated to contribute to the market growth.
Shift Towards Combination Therapies is Poised to Elevate the Liver Disease Treatment Market Value
There is a growing demand for combination therapies in the market as these treatment approaches often result in improved clinical outcomes. For instance, in cases of Hepatitis C and NASH, the combination of antiviral agents with other drug classes is seen to increase efficacy and reduce drug resistance. Thus, the rising preference for combination therapies is set to shape the market dynamics in the forecast period.
Liver Disease Treatment Market Segmentation
Market Breakup by Treatment Type
- Antiviral Drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
- Others
Market Breakup by Disease Type
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic fatty Liver Disease
- Cancer
- Others
Market Breakup by End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Liver Disease Treatment Market Share
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy, among others. The antiviral drugs segment covers a significant market share due to the high prevalence of viral hepatitis such as hepatitis B and C. The development of new antiviral agents with higher efficacy and better safety profiles further boosts the market share. Moreover, the chronic nature of hepatitis B and C, if not treated effectively, necessitates long-term antiviral therapy, which is likely to augment the market demand in the forecast period.
Liver Disease Treatment Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share due to the considerable burden of liver diseases, the presence of advanced healthcare infrastructure, and a strong focus on research and development activities in the region. The high healthcare expenditure allows access to innovative therapies and also supports the development of new treatments in the region. Moreover, the presence of key players in the United States that are engaged in developing antiviral and targeted therapies for liver diseases is expected to bolster the market growth.
Leading Players in the Liver Disease Treatment Market
The key features of the market report comprise the patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Abbott Laboratories
American multinational medical devices and health care company Abbott Laboratories is a prominent player in the market. Its drug SILLIVER® (Silymarin) is indicated for the treatment of liver diseases such as liver cirrhosis, acute hepatitis, and toxic metabolic liver damage. Silymarin is also known to protect against liver damage by general anesthesia.
Bristol-Myers Squibb Company
Headquartered in Princeton, New Jersey, Bristol-Myers Squibb is widely recognized for its innovative treatments including therapies for liver diseases. One of its key medications is the FDA-approved Daklinza (daclatasvir ) taken in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 3.
Gilead Sciences
California-based Gilead Sciences is an American biopharmaceutical company that specializes in the development of antiviral therapies, particularly for liver diseases. Gilead actively collaborates with research institutions and healthcare organizations to boost its research capabilities and expand its portfolio in liver disease treatment.
GlaxoSmithKline PLC
Leading biopharma company GlaxoSmithKline PLC is headquartered in Brentford, United Kingdom, and focuses on the development of vaccine development, antiviral therapies, and innovative treatment approaches for chronic liver conditions.
Other key players in the market include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, AbbVie Inc., and Pfizer Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Breakup by Region |
India |
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Liver Disease Treatment Market Report
- What was the liver disease treatment market value in 2023?
- What is the liver disease treatment market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on disease type?
- Who are the major end users in the market?
- What are the major factors aiding the liver disease treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of liver diseases affect the market landscape?
- What are the major liver disease treatment market trends?
- How do the improvements in diagnostic tools impact the market size?
- Which treatment type will dominate the market share?
- Which disease type is expected to have a high market value in the coming years?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the liver disease treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Liver Disease Treatment Market Overview – 8 Major Markets
3.1 Liver Disease Treatment Market Historical Value (2017-2023)
3.2 Liver Disease Treatment Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Liver Disease Treatment Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Liver Disease Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 United States
7.1.1.2 United Kingdom
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 United States
7.1.2.2 United Kingdom
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 United States
7.1.3.2 United Kingdom
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Liver Disease Treatment Market Landscape – 8 Major Markets
8.1 Liver Disease Treatment Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Liver Disease Treatment Market: Product Landscape
8.2.1 Analysis by Treatment Type
8.2.2 Analysis by Disease Type
9 Liver Disease Treatment Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Liver Disease Treatment Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Liver Disease Treatment Market Segmentation (2017-2032) - 8 Major Markets
12.1 Liver Disease Treatment Market (2017-2032) by Treatment Type
12.1.1 Market Overview
12.1.2 Antiviral Drugs
12.1.3 Immunosuppressants
12.1.4 Vaccines
12.1.5 Corticosteroids
12.1.6 Immunoglobins
12.1.7 Targeted Therapy
12.1.8 Chemotherapy
12.1.9 Others
12.2 Liver Disease Treatment Market (2017-2032) by Disease Type
12.2.1 Market Overview
12.2.2 Hepatitis
12.2.3 Autoimmune Diseases
12.2.4 Non-alcoholic fatty Liver Disease
12.2.5 Cancer
12.2.6 Others
12.3 Liver Disease Treatment Market (2017-2032) by End User
12.3.1 Market Overview
12.3.2 Hospital and Clinics
12.3.3 Diagnostic Centers
12.3.4 Others
12.4 Liver Disease Treatment Market (2017-2032) by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Liver Disease Treatment Market (2017-2032)
13.1 United States Liver Disease Treatment Market Historical Value (2017-2023)
13.2 United States Liver Disease Treatment Market Forecast Value (2024-2032)
13.3 United States Liver Disease Treatment Market (2017-2032) by Treatment Type
13.3.1 Market Overview
13.3.2 Antiviral Drugs
13.3.3 Immunosuppressants
13.3.4 Vaccines
13.3.5 Corticosteroids
13.3.6 Immunoglobins
13.3.7 Targeted Therapy
13.3.8 Chemotherapy
13.3.9 Others
13.4 United States Liver Disease Treatment Market (2017-2032) by Disease Type
13.4.1 Market Overview
13.4.2 Hepatitis
13.4.3 Autoimmune Diseases
13.4.4 Non-alcoholic fatty Liver Disease
13.4.5 Cancer
13.4.6 Others
13.5 United States Liver Disease Treatment Market (2017-2032) by End User
13.5.1 Market Overview
13.5.2 Hospital and Clinics
13.5.3 Diagnostic Centers
13.5.4 Others
14 EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032)
14.1 EU-4 and United Kingdom Liver Disease Treatment Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Liver Disease Treatment Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Antiviral Drugs
14.3.3 Immunosuppressants
14.3.4 Vaccines
14.3.5 Corticosteroids
14.3.6 Immunoglobins
14.3.7 Targeted Therapy
14.3.8 Chemotherapy
14.3.9 Others
14.4 EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032) by Disease Type
14.4.1 Market Overview
14.4.2 Hepatitis
14.4.3 Autoimmune Diseases
14.4.4 Non-alcoholic fatty Liver Disease
14.4.5 Cancer
14.4.6 Others
14.5 EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032) by End User
14.5.1 Market Overview
14.5.2 Hospital and Clinics
14.5.3 Diagnostic Centers
14.5.4 Others
15 Japan Liver Disease Treatment Market
15.1 Japan Liver Disease Treatment Market Historical Value (2017-2023)
15.2 Japan Liver Disease Treatment Market Forecast Value (2024-2032)
15.3 Japan Liver Disease Treatment Market (2017-2032) by Treatment Type
15.3.1 Market Overview
15.3.2 Antiviral Drugs
15.3.3 Immunosuppressants
15.3.4 Vaccines
15.3.5 Corticosteroids
15.3.6 Immunoglobins
15.3.7 Targeted Therapy
15.3.8 Chemotherapy
15.3.9 Others
15.4 Japan Liver Disease Treatment Market (2017-2032) by Disease Type
15.4.1 Market Overview
15.4.2 Hepatitis
15.4.3 Autoimmune Diseases
15.4.4 Non-alcoholic fatty Liver Disease
15.4.5 Cancer
15.4.6 Others
15.5 Japan Liver Disease Treatment Market (2017-2032) by End User
15.5.1 Market Overview
15.5.2 Hospital and Clinics
15.5.3 Diagnostic Centers
15.5.4 Others
16 India Liver Disease Treatment Market
16.1 India Liver Disease Treatment Market (2017-2032) Historical Value (2017-2023)
16.2 India Liver Disease Treatment Market (2017-2032) Forecast Value (2024-2032)
16.3 India Liver Disease Treatment Market (2017-2032) by Treatment Type
16.3.1 Market Overview
16.3.2 Antiviral Drugs
16.3.3 Immunosuppressants
16.3.4 Vaccines
16.3.5 Corticosteroids
16.3.6 Immunoglobins
16.3.7 Targeted Therapy
16.3.8 Chemotherapy
16.3.9 Others
16.4 India Liver Disease Treatment Market (2017-2032) by Disease Type
16.4.1 Market Overview
16.4.2 Hepatitis
16.4.3 Autoimmune Diseases
16.4.4 Non-alcoholic fatty Liver Disease
16.4.5 Cancer
16.4.6 Others
16.5 India Liver Disease Treatment Market (2017-2032) by End User
16.5.1 Market Overview
16.5.2 Hospital and Clinics
16.5.3 Diagnostic Centers
16.5.4 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 Japan PMDA
17.5 India CDSCO
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grants Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Application
20.5 Analysis by Funding Institute
20.6 Analysis by NIH Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Treatment Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Treatment Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Abbott Laboratories
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Company News and Development
23.2.5 Certifications
23.3 Astellas Pharma Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Company News and Development
23.3.5 Certifications
23.4 Bristol- Myers Squibb Company
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Company News and Development
23.4.5 Certifications
23.5 Gilead Sciences
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Company News and Development
23.5.5 Certifications
23.6 GlaxoSmithKline PLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Company News and Development
23.6.5 Certifications
23.7 F. Hoffmann-La Roche Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Company News and Development
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Company News and Development
23.8.5 Certifications
23.9 Novartis AG
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Company News and Development
23.9.5 Certifications
23.10 Sanofi AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Company News and Development
23.10.5 Certifications
23.11 AbbVie Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Company News and Development
23.11.5 Certifications
23.12 Pfizer Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Company News and Development
23.12.5 Certifications
24 Liver Disease Treatment Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER